Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma

Published:2021-11-25 Issue:1 Volume:39 Page:598-618
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Samineni Divya^ORCID,Huang Weize,Gibiansky Leonid,Ding Hao,Zhang Rong,Li Chunze,Sinha Arijit,Rajwanshi Richa,Humphrey Kathryn,Bazeos Alexandra,Salem Ahmed Hamed,Miles Dale

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-021-01919-z.pdf

Reference30 articles.

1. Hata AN, Yeo A, Faber AC, et al. Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. Cancer Res. 2014;74(11):3146–56. https://doi.org/10.1158/0008-5472.CAN-13-3728.

2. Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol. 2018. https://doi.org/10.1098/rsob.180002.

3. Zhang HW, Cheng NL, Chen ZW, Wang JF, Li SH, Bai W. Clinical impact of t(14;18) in diffuse large B-cell lymphoma. Chin J Cancer Res. 2011;23(2):160–4. https://doi.org/10.1007/s11670-011-0160-x.

4. Anderson MA, Tsui A, Wall M, Huang DC, Roberts AW. Current challenges and novel treatment strategies in double hit lymphomas. Ther Adv Hematol. 2016;7(1):52–64. https://doi.org/10.1177/2040620715608091.

5. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8. https://doi.org/10.1038/nm.3048.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetic Models of Venetoclax in Hematologic Malignancies: A Systematic Review;Drug Design, Development and Therapy;2024-05

2. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor;Clinical and Translational Science;2024-05

3. Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review;Frontiers in Pharmacology;2023-11-06

4. Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety;Hematological Oncology;2023-09-23

5. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements;Frontiers in Immunology;2022-08-25